<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3012246503
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1997
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        UNASYN 500:250MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMPICILLIN,SULBACTAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250,125
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        9.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HAUPT PHARMA LATINA S.R.I." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HAUPT PHARMA LATINA S.R.I.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CR01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>UNASYN is a combination medicine that contains ampicillin sodium (a penicillin-like antibiotic) and sulbactam sodium (a medicine that prevents bacteria from destroying ampicillin) for injection into a vein or muscle.</p><p>&nbsp;</p><p>UNASYN belongs to a group of medicines known as &ldquo;antibacterials for systemic use&rdquo;, and acts against infections that can affect different parts of the body.</p><p>&nbsp;</p><p>UNASYN is used for the treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the skin caused by bacteria that have become resistant to ampicillin in adults and children over 1 year of age</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intra-abdominal infections and gynaecological infections caused by bacteria that have become resistant to ampicillin in adults</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mixed infections suspected to be caused by bacteria that have become resistant to ampicillin in adults</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You or your child should not be administered UNASYN:</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a previous history of allergic (hypersensitive) reactions to ampicillin , sulbactam, other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a previous history of liver problems (jaundice or hepatitis) associated with UNASYN.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Special care should be taken with UNASYN:</strong></p><p><strong>&nbsp;</strong></p><p>Before and during treatment with UNASYN, your or your child&rsquo;s doctor will perform some tests to determine whether UNASYN is suitable for you.</p><p>&nbsp;</p><p>Make sure your or your child&rsquo;s doctor knows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had a severe allergic reaction to any type of penicillin or cephalosporin antibiotic</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver disease if you have mononucleosis (also called &ldquo;mono&rdquo; which is an infectious disease usually caused by a herpes virus) as you are likely to develop a skin rash with UNASYN</p><p>&nbsp;</p><p>Antibiotic medicines can cause diarrhea which may be a sign of a new infection. If you develop diarrhea that is watery or bloody, tell your doctor.&nbsp; Do not use anti-diarrhea medicine unless your doctor tells you to.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Taking other medicines with Unasyn </strong></p><p>&nbsp;</p><p>Tell your or your child&rsquo;s doctor if you or your child are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Caution is required if you are taking the following:</p><p>&nbsp;</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probenecid (medicine used to treat gout and build-up of uric acid). This medicine may increase the toxic effects of UNASYN<strong> </strong></p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allopurinol (medicine used to treat gout and build-up of uric acid).&nbsp; Skin rashes may occur if you take this medicine at the same time as UNASYN</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aminoglycosides (antibiotics used to treat aerobic bacterial infections e.g. streptomycin). Aminoglycosides and ampicillin inactivate each other, therefore, if you are taking these medicines together with UNASYN, the two antibiotics should be administered into two different parts of the body and at different times</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant, think you&nbsp; may be pregnant, planning to have a baby or breast-feeding,&nbsp; ask your doctor for advice before being administered this medicine.</p><p>&nbsp;</p><p><strong>Pregnancy:</strong></p><p>There are no adequate and well-controlled studies in pregnant women.&nbsp; UNASYN should be used during pregnancy only if clearly needed.</p><p>&nbsp;</p><p><strong>Breast-feeding:</strong></p><p>UNASYN is excreted in breast milk. Caution should be advised when UNASYN is administered to a nursing woman.</p><p><strong>&nbsp;</strong></p><p><strong>Important information about some of the ingredients of UNASYN</strong></p><p>&nbsp;</p><p>Unasyn contains sodium and should be considered in patients with kidney problems and who are on a low sodium diet</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>UNASYN may be administered either by injection&nbsp; into a vein (intravenous use) or into a&nbsp; muscle (intramuscular use).</p><p>&nbsp;</p><p>You will not be expected to administer UNASYN to yourself&nbsp; or your child.&nbsp; It&nbsp; will be administered to you or your child in a suitable facitity (e.g. in hospital) by a healthcare professional who is qualified to do so.&nbsp;</p><p>&nbsp;</p><p>Your or your child&rsquo;s doctor will decide on the dosage and duration of treatment which may vary depending on the severity and type of infection being treated.&nbsp;</p><p>&nbsp;</p><p>If you or your child have kidney problems, your doctor may prescribe less frequent administration of UNASYN.</p><p>&nbsp;</p><p><strong>If are administered more Unasyn than you should</strong></p><p><strong>&nbsp;</strong></p><p>UNASYN may cause seizures at high doses however, since a healthcare provider will administer this medicine, he/she will control the dosage. In the event of overdosage your or your child&rsquo;s doctor will manage the overdosage.</p><p><em>&nbsp;</em></p><p><strong>If a dose of Unasyn has been forgotten </strong></p><p><strong>&nbsp;</strong></p><p>If you think that a dose has been forgotten, talk to your or your child&rsquo;s doctor.&nbsp; A double dose should not be given to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking using Unasyn</strong></p><p><strong>&nbsp;</strong></p><p>Your or your child&rsquo;s doctor will tell you how long your treatment with UNASYN will last.&nbsp; If you or your child stop treatment early, the outcome of the treatment may be compromised. Talk to your or your child&rsquo;s doctor before stopping or ending treatment with Unasyn.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your or your child&rsquo;s doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, UNASYN can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>If any of the following happens, tell your or your child&rsquo;s doctor immediately:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the hands, feet, ankles, face, lips, mouth or throat, which may cause difficulty in swallowing or breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain relating to reduced blood flow to the heart caused by an allergic reaction or a strong immune reaction to a drug or other substance.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash with itching, redness, swelling and inflammation of the skin. Lesions, blisters, bruising or peeling of the skin, fever, facial swelling, enlargement of lymph node or very rare blistering condition of the skin in a clustered arrangement.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe diarrhoea that is watery or bloody&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin and eyes (also called jaundice)</p><p>&nbsp;</p><p>These are all serious side effects.&nbsp; You may need urgent medical attention.</p><p><strong>&nbsp;</strong></p><p><strong>Tell your or your child&rsquo;s doctor if you notice any of the following other side effects that have been reported in clinical trials:</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain at the injection site</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation and blood clot in a vein</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea and vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal itching or discharge</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling tired, ill or weak</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indigestion or heartburn, swelling of the abdomen</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the tongue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urine retention, difficulty in urinating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills, sore throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nose bleeds</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in mucous</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in laboratory test results such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the blood of certain substances normally produced by the liver</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase or decrease in certain white blood cells</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of proteins in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in blood nitrogen and creatinine levels of the kidney</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in the urine</p><p>A case of severe increase in lymphocytes in the blood has been observed in one paediatric patient.</p><p>&nbsp;</p><p><strong>Other side effects that have been reported include the following:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain and inflammation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the liver</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A stoppage or slowing of the flow of bile</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High levels of bilirubin in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dark or blood stained stools</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Black &ldquo;hairy&rdquo; tongue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures and dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute kidney failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain relating to reduced blood flow to the heart caused by an allergic reaction or a strong immune reaction to a drug or other substance.</p><p>&nbsp;</p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your or your child&rsquo;s doctor.</p><p>&nbsp;</p><p><u>Reporting side effects</u></p><p>If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)</strong></p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website:https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children</p><p>&nbsp;</p><p>Store below 30C.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton ,or vial The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Shelf life: 24 months.</p><p>&nbsp;</p><p>Do not use this medicine if you notice visible signs of deterioration.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are Ampicillin Sodium and Salbactam Sodium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vial containing powder for injectable solution.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Italia S.R.L, Italy</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Haupt Pharma Latina S.R.L, Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2025
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يوناسين هو دواء مركب يحتوي على أمبيسيلين الصوديوم (مضاد حيوي يشبه البنسيلين) وسولباكتام الصوديوم (دواء يمنع البكتيريا من تدمير أمبيسيلين) ومخصص للحقن في أحد الأوردة أو في العضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي يوناسين إلى مجموعة أدوية تسمى &quot;مضادات البكتيريا للاستخدام الجهازي&quot;، ويعمل على مكافحة العدوى التي يمكن أن تؤثر على أجزاء مختلفة من الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم يوناسين لعلاج:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى الجلد الناتجة عن البكتيريا التي أصبحت مقاومة لأمبيسيلين لدى البالغين والأطفال الذين يزيد عمرهم عن عام واحد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى داخل البطن وحالات عدوى الجهاز التناسلي الأنثوي الناتجة عن البكتيريا التي أصبحت مقاومة لأمبيسيلين لدى البالغين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى المختلطة التي يُشتبه في أنها ناتجة عن البكتيريا التي أصبحت مقاومة لأمبيسيلين لدى البالغين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال يوناسين:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك تاريخ سابق من الإصابة بتفاعلات حساسية (فرط الحساسية) تجاه أمبيسيلين، أو سولباكتام، أو العقاقير الأخرى من مضادات البكتيريا بيتا-لاكتام (على سبيل المثال، مركبات البنسيلين والسيفالوسبورينات).</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ سابق من الإصابة بمشكلات الكبد (اليرقان أو التهاب الكبد الوبائي) المرتبطة باستعمال يوناسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات عند استعمال يوناسين:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل وأثناء العلاج بيوناسين، سيقوم طبيبك أو طبيب طفلك بإجراء بعض الاختبارات لتحديد ما إذا كان يوناسين مناسبًا لك أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص على أن يكون طبيبك أو طبيب طفلك على علم بما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بتفاعل حساسية شديد تجاه أي نوع من المضادات الحيوية من فئة البنسيلين أو السيفالوسبورين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض في الكبد، إذا كنت مصابًا بكثرة الوحيدات (يُسمى أيضًا &quot;مرض مونو&quot;، وهو مرض معد عادة ما يكون بسبب فيروس الهربس)، حيث من المرجح أن تصاب بطفح جلدي عند استعمال يوناسين</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تسبب المضادات الحيوية الإسهال الذي قد يكون علامة على الإصابة بعدوى جديدة. إذا أصبت بإسهال مائي أو دموي، فأخبر طبيبك.&nbsp; لا تستخدم دواءً مضادًا للإسهال ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التدخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو طبيب طفلك إذا كنت أنت أو طفلك تتناولان أو تناولتما مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يلزم توخي الحذر إذا كنت تتناول ما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبينسيد (دواء يستخدم لعلاج النقرس وتراكم حمض اليوريك). قد يزيد هذا الدواء من الآثار السامة ليوناسين<strong> </strong></p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألوبيورينول (دواء يستخدم لعلاج النقرس وتراكم حمض اليوريك).&nbsp; قد يحدث طفح جلدي إذا تناولت هذا الدواء في نفس الوقت مع يوناسين</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأمينوجليكوزيدات (مضادات حيوية تستخدم لعلاج حالات العدوى البكتيرية الهوائية مثل ستربتوميسين). تثبط الأمينوجليكوزيدات وأمبيسيلين بعضهما البعض، لذلك إذا كنت تتناول هذه الأدوية بالتزامن مع يوناسين، ينبغي إعطاء المضادين الحيويين في جزأين مختلفين من الجسم وفي أوقات مختلفة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للإنجاب، أو تُرضعين رضاعة طبيعية، فاستشيري طبيبكِ قبل استعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل:</strong></p><p dir="RTL">لا توجد دراسات وافية ومراقبة بشكل ملائم عن السيدات الحوامل.&nbsp; ينبغي عدم استخدام يوناسين أثناء الحمل إلا إذا كانت هناك حاجة واضحة إلى ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية:</strong></p><p dir="RTL">يُفرز يوناسين في لبن الثدي. ينبغي أن يُنصح بتوخي الحذر عند إعطاء يوناسين للسيدات المرضعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات يوناسين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي يوناسين على الصوديوم وينبغي وضع ذلك في الاعتبار مع المرضى الذين يعانون من مشكلات في الكلى والذين يتبعون حمية غذائية منخفضة الصوديوم</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن استعمال يوناسين إما بواسطة الحقن في أحد الأوردة (الحقن عن طريق الوريد) أو في إحدى العضلات (الحقن في العضل).</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">لن يُتوقع منك إعطاء يوناسين لنفسك أو لطفلك.&nbsp; سيتم إعطاؤه لك أو لطفلك في منشأة مناسبة (على سبيل المثال في مستشفى) بواسطة أخصائي رعاية صحية مؤهل للقيام بذلك.&nbsp;</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">سيحدد طبيبك أو طبيب طفلك الجرعة ومدة العلاج اللتين قد تختلفان بناءً على شدة ونوع العدوى التي يتم علاجها.&nbsp;</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">إذا كنت تعاني أنت أو طفلك من مشكلات في الكلى، فقد يصف طبيبك معدل تكرار أقل لاستعمال يوناسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من يوناسين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب يوناسين نوبات عند إعطاء جرعات عالية، ولكن نظرًا لأن مقدم الرعاية الصحية هو من سيقوم بإعطاء هذا الدواء، فسوف يتحكم في الجرعة. في حالة تلقي جرعة مفرطة، سيقوم طبيبك أو طبيب طفلك بإدارة الجرعة المفرطة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة يوناسين </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا اعتقدت أنه قد نُسيت إحدى الجرعات، فتحدث إلى طبيبك أو طبيب طفلك. ينبغي عدم إعطاء جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول يوناسين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك أو طبيب طفلك بالمدة التي سيستمر خلالها علاجك بيوناسين.&nbsp; إذا أوقفت أنت أو طفلك العلاج مبكرًا، فقد يؤثر هذا سلبًا على نتائج العلاج. تحدث إلى طبيبك أو طبيب طفلك قبل إيقاف أو إنهاء العلاج بيوناسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاسأل طبيبك أو طبيب طفلك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب يوناسين آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا حدث أي مما يلي، فأخبر طبيبك أو طبيب طفلك على الفور:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين، أو القدمين، أو الكاحلين، أو الوجه، أو الشفتين، أو الفم، أو الحلق، مما قد يسبب صعوبة في البلع أو التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر المتعلق بانخفاض تدفق الدم إلى القلب نتيجة تفاعل حساسية أو تفاعل مناعي قوي تجاه أحد العقاقير أو مادة أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي المصحوب بحكة، واحمرار الجلد وتورمه والتهابه.&nbsp; تكون آفات أو بثور على الجلد، أو تكدم الجلد أو تقشره، الحمى، أو تورم الوجه، أو تضخم العقد الليمفاوية أو حالة نادرة جدًا من ظهور بثور على الجلد على نحو متجمع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال شديد مائي أو دموي&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعينين (يُسمى أيضًا باليرقان)</p><p dir="RTL">&nbsp;</p><p dir="RTL">جميع هذه الآثار الجانبية خطيرة.&nbsp; وقد تحتاج إلى رعاية طبية عاجلة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر طبيبك أو طبيب طفلك إذا لاحظت أيًا من الآثار الجانبية الأخرى التالية التي تم الإبلاغ عنها في التجارب الإكلينيكية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موضع الحقن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وجلطة دموية في أحد الأوردة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان وقيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة أو إفرازات مهبلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتعب أو المرض أو الضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم أو حرقة المعدة، تورم البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب اللسان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس البول، صعوبة في التبول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة، التهاب الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في المخاط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج الاختبارات المعملية مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة مواد معينة في الدم تنتجها الكبد عادةً</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أو انخفاض في بعض خلايا الدم البيضاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة البروتينات في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في نيتروجين الدم وفي مستويات الكرياتينين في الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البول</p><p dir="RTL">لقد لوحظت حالة زيادة شديدة في الليمفاويات في الدم لدى مريض واحد من الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الآثار الجانبية الأخرى التي تم الإبلاغ عنها ما يلي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم والتهاب المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف أو بطء تدفق الصفراء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات البيليروبين في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال وظائف الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البراز أو تغير لونه إلى لون داكن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لسان أسود &quot;مشعر&quot;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات والدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكلى الحاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر المتعلق بانخفاض تدفق الدم إلى القلب نتيجة تفاعل حساسية أو تفاعل مناعي قوي تجاه أحد العقاقير أو مادة أخرى.</p><p dir="RTL">إذا أصبح أي من الآثار الجانبية خطيرًا أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار طبيبك أو طبيب طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الإبلاغ عن الأعراض الجانبية: </u></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عبر نظام الإبلاغ الوطني. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي</strong></p><ul><li dir="RTL">مركز الاتصال: ١٩٩٩٩</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/</li></ul><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ عند درجة حرارة اقل من 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية أو الزجاجة &lt;يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">صلاحية المستحضر 24 شهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت {وصف علامات التلف الظاهرة}.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المواد الفعالة هي&nbsp; أمبيسيلين الصوديوم، سولباكتام الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>زجاجة تحتوي على مسحوق لتحضير محلول قابل للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق </strong></p><p>Pfizer Italia S.R.L, Italy</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة:</strong></p><p>Haupt Pharma Latina S.R.L, Italy</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير/كانون الثاني ۲۰۲٥
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                UNASYN 250 mg + 500 mg powder for injectable solution 
UNASYN 500 mg + 1 g powder for injectable solution 
UNASYN 1 g + 2 g powder for injectable solution 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                UNASYN 250 mg + 500 mg powder for injectable solution
Active substances:
sulbactam sodium	 273.5 mg (equal to 250 mg of sulbactam) 
ampicillin sodium	 531.5 mg (equal to 500 mg of ampicillin) 

UNASYN 500 mg + 1 g powder for injectable solution for intramuscular use
Active substances:
sulbactam sodium	 547 mg (equal to  500  mg of sulbactam) 
ampicillin sodium	 1,063 mg (equal to 1,000  mg of ampicillin) 

UNASYN 1 g + 2 g powder for injectable solution 
Active substances:
sulbactam sodium:	 1,099 mg (equal to  1,000  mg of sulbactam) 
ampicillin sodium	 2,132 mg (equal to 2,000  mg of ampicillin) 

UNASYN is an injectable antibacterial combination consisting of the semisynthetic antibacterial ampicillin sodium and the beta lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration.

Ampicillin sodium is derived from the penicillin nucleus, 6 aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R) 6 [(R) 2 amino 2-phenylacetamido]-3, 3 dimethyl 7 oxo 4 thia 1 azabicyclo[3.2.0]heptane 2 carboxylate and has a molecular weight of 371.39. Its chemical formula is C16H18N3NaO4S. The structural formula is:













 







Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R) 3,3 dimethyl 7 oxo 4 thia  1 azabicyclo [3.2.0] heptane 2 carboxylate 4,4 dioxide. Its chemical formula is C8H10NNaO5S with a molecular weight of 255.22. The structural formula is:


 

Excipient with known effect:
UNASYN contains Sodium.



 




For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for injectable solution

UNASYN, ampicillin sodium/sulbactam sodium parenteral combination, is available as a white to off white dry powder for reconstitution. UNASYN dry powder is freely soluble in aqueous diluents to yield pale yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL. The pH of the solutions is between 8.0 and 10.0.

Dilute solutions (up to 30 mg ampicillin and 15 mg sulbactam per mL) are essentially colourless to pale yellow. The pH of dilute solutions remains the same.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>UNASYN is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.</p><p>&nbsp;</p><p><strong>Skin and Skin Structure Infections</strong> caused by beta‑lactamase producing strains of <em>Staphylococcus aureus</em>, <em>Escherichia coli</em>,* <em>Klebsiella</em> spp.* (including <em>K. pneumoniae*</em>), <em>Proteus mirabilis</em>,* <em>Bacteroides fragilis</em>,* <em>Enterobacter</em> spp.,* and <em>Acinetobacter calcoaceticus.*</em></p><p>&nbsp;</p><p>NOTE: For information on use in pediatric patients (see sections<strong> </strong>4.4<strong> </strong>and 5.1<strong>)</strong>.</p><p>&nbsp;</p><p><strong>Intra‑Abdominal Infections</strong> caused by beta‑lactamase producing strains of <em>Escherichia coli</em>, <em>Klebsiella</em> spp. (including <em>K. pneumoniae*</em>), <em>Bacteroides</em> spp. (including <em>B. fragilis</em>), and <em>Enterobacter</em> spp.*</p><p>&nbsp;</p><p><strong>Gynecological Infections</strong> caused by beta‑lactamase producing strains of <em>Escherichia coli,*</em> and <em>Bacteroides</em> spp.* (including <em>B. fragilis*</em>).</p><p>&nbsp;</p><p>* Efficacy for this organism in this organ system was studied in fewer than 10 infections.</p><p>&nbsp;</p><p>While UNASYN is indicated only for the conditions listed above, infections caused by ampicillin‑susceptible organisms are also amenable to treatment with UNASYN due to its ampicillin content. Therefore, mixed infections caused by ampicillin‑susceptible organisms and beta‑lactamase producing organisms susceptible to UNASYN should not require the addition of another antibacterial.</p><p>&nbsp;</p><p>Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to UNASYN.</p><p>&nbsp;</p><p>Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta‑lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate.</p><p>&nbsp;</p><p>To reduce the development of drug-resistant bacteria and maintain effectiveness of UNASYN and other antibacterial drugs, UNASYN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>UNASYN may be administered by either the IV or the IM routes.</p><p>&nbsp;</p><p>For IV administration, the dose can be given by slow intravenous injection over at least 10&ndash;15 minutes or can also be delivered in greater dilutions with 50&ndash;100 mL of a compatible diluent as an intravenous infusion over 15&ndash;30 minutes.</p><p>&nbsp;</p><p>UNASYN may be administered by deep intramuscular injection. (see section 6.6).</p><p>&nbsp;</p><p>The recommended adult dosage of UNASYN is 1.5&nbsp;g (1&nbsp;g ampicillin as the sodium salt plus 0.5&nbsp;g sulbactam as the sodium salt) to 3&nbsp;g (2&nbsp;g ampicillin as the sodium salt plus 1&nbsp;g sulbactam as the sodium salt) every six hours. This 1.5 to 3&nbsp;g range represents the total of ampicillin content plus the sulbactam content of UNASYN, and corresponds to a range of 1&nbsp;g ampicillin/0.5&nbsp;g sulbactam to 2&nbsp;g ampicillin/1&nbsp;g sulbactam. The total dose of sulbactam should not exceed 4&nbsp;grams per day.</p><p>&nbsp;</p><p><strong>Pediatric Patients 1 Year of Age or Older:</strong> The recommended daily dose of UNASYN in pediatric patients is 300&nbsp;mg per kg of body weight administered via intravenous infusion in equally divided doses every 6 hours. This 300&nbsp;mg/kg/day dosage represents the total ampicillin content plus the sulbactam content of UNASYN, and corresponds to 200&nbsp;mg ampicillin/100&nbsp;mg sulbactam per kg per day. The safety and efficacy of UNASYN administered via intramuscular injection in pediatric patients have not been established. Pediatric patients weighing 40&nbsp;kg or more should be dosed according to adult recommendations, and the total dose of sulbactam should not exceed 4&nbsp;grams per day. The course of intravenous therapy should not routinely exceed 14&nbsp;days. In clinical trials, most children received a course of oral antimicrobials following initial treatment with intravenous UNASYN. (see<strong> </strong>section<strong> </strong>5.1).</p><p>&nbsp;</p><p><strong>Impaired Renal Function</strong></p><p>In patients with impairment of renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of UNASYN in such patients should be administered less frequently in accordance with the usual practice for ampicillin and according to the following recommendations:</p><p>&nbsp;</p><p><strong>TABLE 1</strong></p><p><strong>UNASYN Dosage Guide for Patients with Renal Impairment</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance</strong></p><p><strong>(mL/min/1.73m<sup>2</sup>)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Ampicillin/Sulbactam</strong></p><p><strong>Half‑Life (Hours)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Recommended</strong></p><p><strong>UNASYN Dosage </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&sup3;30</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; 1.5&ndash;3 g q 6h‑q 8h</p></td></tr><tr><td style="vertical-align:top"><p>15&ndash;29</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; 1.5&ndash;3 g q 12h</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; 5&ndash;14</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; 1.5&ndash;3 g q 24h</p></td></tr></tbody></table><p>&nbsp;</p><p>When only serum creatinine is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Males&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>weight (kg) </u><u>&acute;</u><u> (140 &ndash; age)</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; 72 &acute; serum creatinine</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Females&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.85 &acute; above value</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The use of UNASYN is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam or to other
beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).

UNASYN is contraindicated in patients with a previous history of cholestatic jaundice/hepatic
dysfunction associated with UNASYN.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>WARNINGS</strong></p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more apt to occur in individuals with a history of penicillin hypersensitivity and/or hypersensitivity reactions to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before therapy with a penicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens. If an allergic reaction occurs, UNASYN should be discontinued and the appropriate therapy instituted.</p><p>&nbsp;</p><p><u>Hepatotoxicity</u></p><p>Hepatic dysfunction, including hepatitis and cholestatic jaundice has been associated with the use of UNASYN. Hepatic toxicity is usually reversible; however, deaths have been reported. Hepatic function should be monitored at regular intervals in patients with hepatic impairment.</p><p>&nbsp;</p><p><u>Severe Cutaneous Adverse Reactions</u></p><p>UNASYN may cause severe skin reactions, such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), dermatitis exfoliative, erythema multiforme, and Acute generalized exanthematous pustulosis (AGEP). If patients develop a skin rash they should be monitored closely and UNASYN discontinued if lesions progress (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p><em><u>Clostridioides</u></em><em><u> difficile</u></em><u>-Associated Diarrhea</u></p><p><em>Clostridioides</em><em> difficile</em> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including UNASYN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <em>C. difficile</em>.</p><p>&nbsp;</p><p><em>C. difficile</em> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <em>C. difficile</em> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p><p>&nbsp;</p><p>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <em>C. difficile</em> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <em>C. difficile</em>, and surgical evaluation should be instituted as clinically indicated.</p><p>&nbsp;</p><p><strong>PRECAUTIONS</strong></p><p>&nbsp;</p><p><u>General </u></p><p>A high percentage of patients with mononucleosis who receive ampicillin develop a skin rash. Thus, ampicillin class antibacterial should not be administered to patients with mononucleosis. In patients treated with UNASYN the possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving <em>Pseudomonas</em> or <em>Candida</em>), the drug should be discontinued and/or appropriate therapy instituted.</p><p>&nbsp;</p><p>Prescribing UNASYN in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p><p>&nbsp;</p><p><u>Information for Patients </u></p><p>Patients should be counseled that antibacterial drugs including UNASYN should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When UNASYN is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1)&nbsp;decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by UNASYN or other antibacterial drugs in the future.</p><p>&nbsp;</p><p>Diarrhea is a common problem caused by antibacterial which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterial, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial.&nbsp; If this occurs, patients should contact their physician as soon as possible.</p><p>&nbsp;</p><p><u>Drug/Laboratory Test Interactions </u></p><p>Administration of UNASYN will result in high urine concentration of ampicillin. High urine concentrations of ampicillin may result in false positive reactions when testing for the presence of glucose in urine using Clinitest&trade;, Benedict&rsquo;s Solution or Fehling&rsquo;s Solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix&trade; or Testape&trade;) be used. Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol‑glucuronide, conjugated estrone and estradiol has been noted. This effect may also occur with UNASYN.</p><p>&nbsp;</p><p><u>Pediatric Use</u></p><p>The safety and effectiveness of UNASYN have been established for pediatric patients one year of age and older for skin and skin structure infections as approved in adults. Use of UNASYN in pediatric patients is supported by evidence from adequate and well‑controlled studies in adults with additional data from pediatric pharmacokinetic studies, a controlled clinical trial conducted in pediatric patients and post-marketing adverse events surveillance. (see sections<strong> </strong>5.2, 4.1, 4.8, 4.2, and 5.1<strong>)</strong>.</p><p>&nbsp;</p><p>The safety and effectiveness of UNASYN have not been established for pediatric patients for intra-abdominal infections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Probenecid decreases the renal tubular secretion of ampicillin and sulbactam. Concurrent use of probenecid with UNASYN may result in increased and prolonged blood levels of ampicillin and sulbactam. The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with UNASYN and allopurinol administered concurrently.</p><p>&nbsp;</p><p>UNASYN and aminoglycosides should not be reconstituted together due to the <em>in vitro</em> inactivation of aminoglycosides by the ampicillin component of UNASYN.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>Reproduction studies have been performed in mice, rats, and rabbits at doses up to ten (10) times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to UNASYN. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. (see section 4.4).</p><p>&nbsp;</p><p><em>Labor and Delivery </em></p><p>Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions. However, it is not known whether the use of UNASYN in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.</p><p>&nbsp;</p><p><em>Nursing Mothers</em></p><p>Low concentrations of ampicillin and sulbactam are excreted in the milk; therefore, caution should be exercised when UNASYN is administered to a nursing woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adult Patients: </strong>UNASYN is generally well tolerated. The following adverse reactions have been reported in clinical trials.</p><p>&nbsp;</p><p><strong>Local Adverse Reactions</strong></p><p>Pain at IM injection site &ndash; 16%</p><p>Pain at IV injection site &ndash; 3%</p><p>Thrombophlebitis &ndash; 3%</p><p>Phlebitis &ndash; 1.2%</p><p><strong>&nbsp;</strong></p><p><strong>Systemic Adverse Reactions</strong></p><p>The most frequently reported adverse reactions were diarrhea in 3% of the patients and rash in less than 2% of the patients.</p><p>&nbsp;</p><p>Additional systemic reactions reported in less than 1% of the patients were: itching, nausea, vomiting, candidiasis, fatigue, malaise, headache, chest pain, flatulence, abdominal distension, glossitis, urine retention, dysuria, edema, facial swelling, erythema, chills, tightness in throat, substernal pain, epistaxis and mucosal bleeding.</p><p>&nbsp;</p><p><strong>Pediatric Patients:</strong> Available safety data for pediatric patients treated with UNASYN demonstrate a similar adverse events profile to those observed in adult patients. Additionally, atypical lymphocytosis has been observed in one pediatric patient receiving UNASYN.</p><p><strong>&nbsp;</strong></p><p><strong>Adverse Laboratory Changes</strong></p><p>Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were:</p><p>&nbsp;</p><p><em>Hepatic:</em> Increased AST (SGOT), ALT (SGPT), alkaline phosphatase, and LDH.</p><p><em>Hematologic:</em> Decreased hemoglobin, hematocrit, RBC, WBC, neutrophils, lymphocytes, platelets and increased lymphocytes, monocytes, basophils, eosinophils, and platelets.</p><p><em>Blood Chemistry:</em> Decreased serum albumin and total proteins.</p><p><em>Renal:</em> Increased BUN and creatinine.</p><p><em>Urinalysis:</em> Presence of RBC&rsquo;s and hyaline casts in urine.</p><p>&nbsp;</p><p><strong>Postmarketing Experience</strong></p><p>In addition to adverse reactions reported from clinical trials, the following have been identified during post-marketing use of ampicillin sodium/sulbactam sodium or other products containing ampicillin. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency, or potential causal connection to ampicillin sodium/sulbactam sodium.</p><p><strong>&nbsp;</strong></p><p><strong>Infections and Infestations:</strong> <em>Clostridioides difficile</em>-<em> </em>associated diarrhea (see section 4.4).</p><p>&nbsp;</p><p><strong>Blood and Lymphatic System Disorders:</strong> Hemolytic anemia, thrombocytopenic purpura, and agranulocytosis have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Some individuals have developed positive direct Coombs Tests during treatment with UNASYN, as with other beta-lactam antibacterials.</p><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal Disorders:</strong> Abdominal pain, cholestatic hepatitis, cholestasis, hyperbilirubinemia, jaundice, abnormal hepatic function, melena, gastritis, stomatitis, dyspepsia, and black &ldquo;hairy&rdquo; tongue. (see sections<strong> </strong>4.3 and 4.4).</p><p>&nbsp;</p><p><strong>General Disorders and Administration Site Conditions:</strong> Injection site reaction</p><p><strong>&nbsp;</strong></p><p><strong>Immune System Disorders:</strong> Serious and fatal hypersensitivity (anaphylactic) reactions (See<strong> </strong>4.4), Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction.</p><p><strong>&nbsp;</strong></p><p><strong>Nervous System Disorders: </strong>Convulsion and dizziness</p><p><strong>&nbsp;</strong></p><p><strong>Renal and Urinary Disorders:</strong> Tubulointerstitial nephritis</p><p><strong>&nbsp;</strong></p><p><strong>Musculoskeletal and Connective Tissue Disorders:</strong> Arthralgia</p><p>&nbsp;</p><p><strong>Respiratory, Thoracic and Mediastinal Disorders: </strong>Dyspnea</p><p><strong>&nbsp;</strong></p><p><strong>Skin and Subcutaneous Tissue Disorders: </strong>Toxic<strong> </strong>epidermal necrolysis, Stevens‑Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), angioedema, Acute generalized exanthematous pustulosis (AGEP), erythema multiforme, exfoliative dermatitis, and urticaria (see sections<strong> </strong>4.3<strong> </strong>and 4.4) and linear IgA bullous dermatosis.</p><p>&nbsp;</p><p><u>Reporting of adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local requirements.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center : 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Neurological adverse reactions, including convulsions, may occur with the attainment of high CSF levels of beta‑lactams. Ampicillin may be removed from circulation by hemodialysis. The molecular weight, degree of protein binding and pharmacokinetics profile of sulbactam suggest that this compound may also be removed by hemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic Group: Antibacterial agents for systemic use.</p><p>Penicillin combinations, including beta-lactamase inhibitors.</p><p>ATC code: J01CR01</p><p>&nbsp;</p><p><strong>MICROBIOLOGY</strong></p><p>&nbsp;</p><p><u>Mechanism of Action</u></p><p>Ampicillin is similar to benzyl penicillin in its bactericidal action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of cell wall mucopeptide biosynthesis. Ampicillin has a broad spectrum of bactericidal activity against many gram‑positive and gram‑negative aerobic and anaerobic bacteria. (Ampicillin is, however, degraded by beta‑lactamases and therefore the spectrum of activity does not normally include organisms which produce these enzymes).</p><p>&nbsp;</p><p>A wide range of beta‑lactamases found in microorganisms resistant to penicillins and cephalosporins have been shown in biochemical studies with cell free bacterial systems to be irreversibly inhibited by sulbactam. Although sulbactam alone possesses little useful antibacterial activity except against the <em>Neisseriaceae</em>, whole organism studies have shown that sulbactam restores ampicillin activity against beta‑lactamase producing strains. In particular, sulbactam has good inhibitory activity against the clinically important plasmid mediated beta‑lactamases most frequently responsible for transferred drug resistance. Sulbactam has no effect on the activity of ampicillin against ampicillin susceptible strains.</p><p>&nbsp;</p><p>The presence of sulbactam in the UNASYN formulation effectively extends the antibacterial spectrum of ampicillin to include many bacteria normally resistant to it and to other beta‑lactam antibacterials. Thus, UNASYN possesses the properties of a broad‑spectrum antibacterial and a beta‑lactamase inhibitor.</p><p>&nbsp;</p><p><u>Antimicrobial Activity</u></p><p>While <em>in vitro</em> studies have demonstrated the susceptibility of most strains of the following organisms, clinical efficacy for infections other than those included in the Posology and method of administration section has not been documented.</p><p>&nbsp;</p><p><strong>Gram‑positive Bacteria:</strong></p><p><em>Staphylococcus aureus</em> (beta‑lactamase and non‑beta‑lactamase producing)</p><p><em>Staphylococcus epidermidis</em> (beta‑lactamase and non‑beta‑lactamase producing)</p><p><em>Staphylococcus saprophyticus</em> (beta‑lactamase and non‑beta‑lactamase producing)</p><p><em>Enterococcus</em> <em>faecalis</em><sup>&dagger;</sup></p><p><em>Streptococcus pneumoniae</em><sup>&dagger;</sup></p><p><em>Streptococcus pyogenes</em><sup>&dagger;</sup></p><p><em>Streptococcus viridans</em><sup>&dagger;</sup></p><p>&nbsp;</p><p><strong>Gram‑negative Bacteria:</strong></p><p><em>Hemophilus influenzae</em> (beta‑lactamase and non‑beta‑lactamase producing)</p><p><em>Moraxella catarrhalis</em> (beta‑lactamase and non‑beta‑lactamase producing)</p><p><em>Escherichia coli</em> (beta‑lactamase and non‑beta‑lactamase producing)</p><p><em>Klebsiella </em>species (all known strains are beta‑lactamase producing)</p><p><em>Proteus mirabilis</em> (beta‑lactamase and non‑beta‑lactamase producing)</p><p><em>Proteus vulgaris</em></p><p><em>Providencia rettgeri</em></p><p><em>Providencia stuartii</em></p><p><em>Morganella morganii</em></p><p><em>Neisseria gonorrhoeae</em> (beta‑lactamase and non‑beta‑lactamase producing)</p><p>&nbsp;</p><p><strong>Anaerobes:</strong> <em>Clostridium</em> species<sup>&dagger;</sup></p><p><em>Peptococcus </em>species<sup>&dagger;</sup></p><p><em>Peptostreptococcus </em>species</p><p><em>Bacteroides</em> species, including <em>B. fragilis</em></p><p>&nbsp;</p><p><sup>&dagger; </sup>These are not beta‑lactamase producing strains and, therefore, are susceptible to ampicillin alone.</p><p>&nbsp;</p><p><strong>Susceptibility Testing</strong></p><p>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</p><p>&nbsp;</p><p><strong>Clinical Studies </strong></p><p><strong>&nbsp;</strong></p><p><strong>Skin and Skin Structure Infections in Pediatric Patients:</strong> Data from a controlled clinical trial conducted in pediatric patients provided evidence supporting the safety and efficacy of UNASYN for the treatment of skin and skin structure infections. Of 99&nbsp;pediatric patients evaluable for clinical efficacy, 60&nbsp;patients received a regimen containing intravenous UNASYN, and 39&nbsp;patients received a regimen containing intravenous cefuroxime. This trial demonstrated similar outcomes (assessed at an appropriate interval after discontinuation of all antimicrobial therapy) for UNASYN- and cefuroxime-treated patients:</p><p>&nbsp;</p><p><strong>TABLE 2</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong><u>Therapeutic Regimen</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Clinical Success</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Clinical Failure</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>UNASYN</p></td><td style="vertical-align:top"><p>51/60 (85%)</p></td><td style="vertical-align:top"><p>9/60 (15%)</p></td></tr><tr><td style="vertical-align:top"><p>Cefuroxime</p></td><td style="vertical-align:top"><p>34/39 (87%)</p></td><td style="vertical-align:top"><p>5/39 (13%)</p></td></tr></tbody></table><p>&nbsp;</p><p>Most patients received a course of oral antimicrobials following initial treatment with intravenous administration of parenteral antimicrobials. The study protocol required that the following three criteria be met prior to transition from intravenous to oral antimicrobial therapy: (1) receipt of a minimum of 72 hours of intravenous therapy; (2) no documented fever for prior 24 hours; and (3) improvement or resolution of the signs and symptoms of infection.</p><p>&nbsp;</p><p>The choice of oral antimicrobial agent used in this trial was determined by susceptibility testing of the original pathogen, if isolated, to oral agents available. The course of oral antimicrobial therapy should not routinely exceed 14 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General:</strong></p><p>Immediately after completion of a 15‑minute intravenous infusion of UNASYN, peak serum concentrations of ampicillin and sulbactam are attained. Ampicillin serum levels are similar to those produced by the administration of equivalent amounts of ampicillin alone. Peak ampicillin serum levels ranging from 109 to 150&nbsp;mcg/mL are attained after administration of 2000&nbsp;mg of ampicillin plus 1000&nbsp;mg sulbactam and 40 to 71&nbsp;mcg/mL after administration of 1000&nbsp;mg ampicillin plus 500&nbsp;mg sulbactam. The corresponding mean peak serum levels for sulbactam range from 48 to 88&nbsp;mcg/mL and 21 to 40&nbsp;mcg/mL, respectively. After an intramuscular injection of 1000&nbsp;mg ampicillin plus 500&nbsp;mg sulbactam, peak ampicillin serum levels ranging from 8 to 37&nbsp;mcg/mL and peak sulbactam serum levels ranging from 6 to 24&nbsp;mcg/mL are attained.</p><p>&nbsp;</p><p>The mean serum half‑life of both drugs is approximately 1 hour in healthy volunteers.</p><p>&nbsp;</p><p>Approximately 75 to 85% of both ampicillin and sulbactam are excreted unchanged in the urine during the first 8 hours after administration of UNASYN to individuals with normal renal function. Somewhat higher and more prolonged serum levels of ampicillin and sulbactam can be achieved with the concurrent administration of probenecid.</p><p>&nbsp;</p><p>In patients with impaired renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of UNASYN in such patients should be administered less frequently in accordance with the usual practice for ampicillin (see section 4.2).</p><p>&nbsp;</p><p>Ampicillin has been found to be approximately 28% reversibly bound to human serum protein and sulbactam approximately 38% reversibly bound.</p><p>&nbsp;</p><p>The following average levels of ampicillin and sulbactam were measured in the tissues and fluids listed:</p><p>&nbsp;</p><p><strong>TABLE 3</strong></p><p><strong>Concentration of UNASYN in Various Body Tissues and Fluids</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>Fluid or Tissue</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose</strong></p><p><strong>(grams)</strong></p><p><strong>Ampicillin/Sulbactam</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Concentration</strong></p><p><strong>(mcg/mL or mcg/g)</strong></p><p><strong>Ampicillin/Sulbactam</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Peritoneal Fluid</p></td><td style="vertical-align:top"><p>0.5/0.5 IV</p></td><td style="vertical-align:top"><p>7/14</p></td></tr><tr><td style="vertical-align:top"><p>Blister Fluid (Cantharides)</p></td><td style="vertical-align:top"><p>0.5/0.5 IV</p></td><td style="vertical-align:top"><p>8/20</p></td></tr><tr><td style="vertical-align:top"><p>Tissue Fluid</p></td><td style="vertical-align:top"><p>1/0.5 IV</p></td><td style="vertical-align:top"><p>8/4</p></td></tr><tr><td style="vertical-align:top"><p>Intestinal Mucosa</p></td><td style="vertical-align:top"><p>0.5/0.5 IV</p></td><td style="vertical-align:top"><p>11/18</p></td></tr><tr><td style="vertical-align:top"><p>Appendix</p></td><td style="vertical-align:top"><p>2/1 IV</p></td><td style="vertical-align:top"><p>3/40</p></td></tr></tbody></table><p>&nbsp;</p><p>Penetration of both ampicillin and sulbactam into cerebrospinal fluid in the presence of inflamed meninges has been demonstrated after IV administration of UNASYN.</p><p>&nbsp;</p><p>The pharmacokinetics of ampicillin and sulbactam in pediatric patients receiving UNASYN are similar to those observed in adults. Immediately after a 15‑minute infusion of 50 to 75&nbsp;mg UNASYN/kg body weight, peak serum and plasma concentrations of 82 to 446&nbsp;mcg ampicillin/mL and 44 to 203&nbsp;mcg sulbactam/mL were obtained. Mean half‑life values were approximately 1&nbsp;hour</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, Mutagenesis, Impairment of Fertility </u></p><p>Long‑term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When concomitant therapy with aminoglycosides is indicated, UNASYN and aminoglycosides should be reconstituted and administered separately, due to the <em>in vitro</em> inactivation of aminoglycosides by any of the aminopenicillins.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use UNASYN after the expiry date which is stated on the vial label after EXP:. The expiry date refers to the last day of that month.

Shelf life: 24 months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>UNASYN sterile powder is to be stored below 30&deg;C (86&deg;F) prior to reconstitution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear, colorless Type III glass vials with bromobutyl rubber stoppers, aluminum caps, and colored flip-off over-caps.</p><p>&nbsp;</p><p>It may be available in vials of:</p><p>- 250 mg + 500 mg powder for injectable solution</p><p>- 500 mg + 1 g powder for injectable solution</p><p>- 1g + 2 g powder for injectable solution</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p><em>&nbsp;</em></p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p><strong>&nbsp;</strong></p><p><strong>INSTRUCTIONS FOR USE:</strong></p><p>&nbsp;</p><p><strong>General Dissolution Procedures:</strong></p><p>UNASYN sterile powder for intravenous and intramuscular use may be reconstituted with any of the compatible diluents described in this insert. Solutions should be allowed to stand after dissolution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization.</p><p><strong>&nbsp;</strong></p><p><strong>Preparation for Intravenous Use</strong></p><p>1.5&nbsp;g and 3.0&nbsp;g Bottles: UNASYN sterile powder in piggyback units may be reconstituted directly to the desired concentrations using any of the following parenteral diluents. Reconstitution of UNASYN, at the specified concentrations, with these diluents provide stable solutions for the time periods indicated in the following table: (After the indicated time periods, any unused portions of solutions should be discarded).</p><p>&nbsp;</p><p><strong>TABLE 4</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Diluent </strong></p></td><td style="vertical-align:top"><p><strong>Maximum Concentration (mg/mL)</strong></p><p><strong>UNASYN (Ampicillin/Sulbactam)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Use Periods</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sterile Water for Injection</p></td><td style="vertical-align:top"><p>45 (30/15)</p><p>45 (30/15)</p><p>30 (20/10)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 hrs at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25&deg;C</p><p>48 hrs at 4&deg;C</p><p>72 hrs at 4&deg;C</p></td></tr><tr><td style="vertical-align:top"><p>0.9% Sodium Chloride Injection</p></td><td style="vertical-align:top"><p>45 (30/15)</p><p>45 (30/15)</p><p>30 (20/10)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 hrs at&nbsp;&nbsp;&nbsp; 25&deg;C</p><p>48 hrs at 4&deg;C</p><p>72 hrs at 4&deg;C</p></td></tr><tr><td style="vertical-align:top"><p>5% Dextrose Injection</p></td><td style="vertical-align:top"><p>30 (20/10)</p><p>30 (20/10)</p><p>3 (2/1)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 hrs at&nbsp;&nbsp;&nbsp; 25&deg;C</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 hrs at&nbsp;&nbsp;&nbsp; 4&deg;C</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 hrs at&nbsp;&nbsp;&nbsp; 25&deg;C</p></td></tr><tr><td style="vertical-align:top"><p>Lactated Ringer&rsquo;s Injection</p></td><td style="vertical-align:top"><p>45 (30/15)</p><p>45 (30/15)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 hrs at&nbsp;&nbsp;&nbsp; 25&deg;C</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24 hrs a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&deg;C</p></td></tr><tr><td style="vertical-align:top"><p>M/6 Sodium Lactate Injection</p></td><td style="vertical-align:top"><p>45 (30/15)</p><p>45 (30/15)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 hrs at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25&deg;C</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 hrs at&nbsp;&nbsp;&nbsp; 4&deg;C</p></td></tr><tr><td style="vertical-align:top"><p>5% Dextrose in 0.45% Saline</p></td><td style="vertical-align:top"><p>3 (2/1)</p><p>15 (10/5)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 hrs at&nbsp;&nbsp;&nbsp; 25&deg;C</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 hrs at&nbsp;&nbsp;&nbsp; 4&deg;C</p></td></tr><tr><td style="vertical-align:top"><p>10% Invert Sugar</p></td><td style="vertical-align:top"><p>3 (2/1)</p><p>30 (20/10)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 hrs at&nbsp;&nbsp;&nbsp; 25&deg;C</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 hrs at&nbsp;&nbsp;&nbsp; 4&deg;C</p></td></tr></tbody></table><p>&nbsp;</p><p>If piggyback bottles are unavailable, standard vials of UNASYN sterile powder may be used. Initially, the vials may be reconstituted with Sterile Water for Injection to yield solutions containing 375&nbsp;mg UNASYN per mL (250&nbsp;mg ampicillin/125&nbsp;mg sulbactam per mL). An appropriate volume should then be immediately diluted with a suitable parenteral diluent to yield solutions containing 3 to 45&nbsp;mg UNASYN per mL (2 to 30&nbsp;mg ampicillin/1 to 15&nbsp;mg sulbactam/per mL).</p><p>&nbsp;</p><p><strong>Preparation for Intramuscular Injection</strong></p><p><strong>1.5 g and 3.0 g Standard Vials:</strong> Vials for intramuscular use may be reconstituted with Sterile Water for Injection USP, 0.5% Lidocaine Hydrochloride Injection USP or 2% Lidocaine Hydrochloride Injection USP. Consult the following table for recommended volumes to be added to obtain solutions containing 375&nbsp;mg UNASYN per mL (250&nbsp;mg ampicillin/125&nbsp;mg sulbactam per mL). Note: <em>Use only freshly prepared solutions and administer within one hour after preparation.</em></p><p>&nbsp;</p><p><strong>TABLE 5</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNASYN</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vial Size</strong></p></td><td style="vertical-align:top"><p><strong>Volume of Diluent</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to be Added</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdrawal</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Volume*</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.5 g</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.2 mL</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.0 mL</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.0 g</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.4 mL</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.0 mL</p></td></tr></tbody></table><p>*<sup>There is sufficient excess present to allow withdrawal and administration of the stated volumes.</sup></p><p><strong>&nbsp;</strong></p><p><strong>Animal Pharmacology:</strong> While reversible glycogenosis was observed in laboratory animals, this phenomenon was dose- and time-dependent and is not expected to develop at the therapeutic doses and corresponding plasma levels attained during the relatively short periods of combined ampicillin/sulbactam therapy in man.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
MARKETING AUTHORISATION HOLDER
Pfizer Italia S.R.L, Italy

MANUFACUTRED BY
Haupt Pharma Latina S.R.L, Italy 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2025
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>